| Outcome Measures: |
Primary: After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-t), Start of treatment up to Day 26|After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-∞), Start of treatment up to Day 26|After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax), Start of treatment up to Day 26 | Secondary: After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Time to maximum concentration (Tmax), Start of treatment up to Day 26|After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Apparent terminal half-life (t1/2), Start of treatment up to Day 26|After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Clearance (CL/F), Start of treatment up to Day 26|After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Apparent volume of distribution (Vz/F), Start of treatment up to Day 26|Safety indicators: Adverse events (AE, including Injection site reactions, Hypoglycemia events, etc.), serious adverse events (SAE)., Screening period up to Day 26|Immunogenicity indicators: anti-Noiiglutide antibodies, Start of treatment up to Day 26|Immunogenicity indicators: anti-INS068 antibodies, Start of treatment up to Day 26
|
